ASCO 2020：11项中国研究成果入选口头报告，17项Poster报告

受全球新冠疫情冲击，如期于5年底29日~6年底2日在芝加哥举行的美国临床学会（ASCO）年会今年将首次以线上形式举办，这是目前最大规模的线上盛会。今天，联席会议的参考资料题目确认，共五103个sessions，欧美共五有11项研究者表现出色口头报告，17项表现出色Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

巯基替尼或拉帕替尼加卡培他滨使用HER2+分散适度乳乳癌（PHOEBE）：一项III期随机实验。

三场：分散适度乳乳癌

编者：欧美医学科学院诊所徐兵河大学教授、马飞大学教授，南京大学附属诊所胡夕春大学教授等

参考资料号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴适度乳乳癌标准放射治疗后卡培他滨延续节拍化学疗法的III期实验（SYSUCC-001）。

三场：乳乳癌—大面积/区域/基本功能放射治疗

编者：南京大学防治中心王以树森大学教授等

参考资料号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

能用分散适度脑部的表型特征来预测脑部脊液中周而复始DNA检查的可能性: 新工具对抗来由赢

三场：新工具应对来由情况

编者：李美芹 李昔等

参考资料号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

伊克非尼对比索拉非尼作为中后期肾脏细胞膜乳癌的梯队放射治疗：一项停止使用标记、随机、多中心II/III期实验。

三场：小肠乳癌—胃部食管、胰腺和肾脏胆

编者：重庆大学索科利夫卡诊所毕锋大学教授、欧美暴政武装警察部队新华诊所秦叔逵大学教授等

参考资料号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

欧美中后期肾脏乳癌病患阿帕替尼二线放射治疗：一项随机、安慰剂印证、CPAIII期研究者

三场：小肠乳癌—胃部食管、胰腺和肾脏胆

编者：欧美暴政武装警察部队新华诊所秦叔逵大学教授、重庆大学索科利夫卡诊所李秋大学教授等

参考资料号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

中后期暂时适度卵巢乳癌二次细胞膜减灭术的一项随机III期实验：SOC1 / SGOG-OV2。

专题：妇科结核病

编者：南京大学附属中山诊所臧荣余大学教授等

参考资料：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈乳癌根治适度子宫矫正后基本功能放射治疗中的序贯放化学疗法对比基本上化疗或启动时放化学疗法（STARS研究者）：一项随机、印证、停止使用标记的III期实验。

联席会议：妇科结核病

编者：南京大学防治中心黄鹤大学教授、刘继红大学教授等

参考资料号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：基本功能吉非替尼对比化学疗法使用可切除的EGFR甲基化的N1-N2期NSCLC-随机III期临床实验的再次总体生存比对。

专题：前列腺乳癌—非小细胞膜大面积-区域/小细胞膜/其他腹部

编者：广东省暴政诊所吴一龙大学教授等

参考资料号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR甲基化寡分散非小细胞膜前列腺乳癌病患梯队组氨酸嘌呤类似物联合行动或不联合行动积极战场大面积化疗：III期停止使用标记临床随机实验（SINDAS）的中期结果（NCT02893332）。

专题：前列腺乳癌-非小细胞膜分散

编者：四川省暴政诊所曾铭大学教授等

参考资料：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序适度生还-1（PD-1）的人源化IgG4单克隆抗体联合行动阿昔替尼使用分散适度黏膜卵巢乳癌病患的Ib期研究者的总生存期和生物；也比对。

专题：卵巢乳癌/皮肤乳癌

编者：北京大学诊所郭军、盛锡楠大学教授等

参考资料：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全适度和结果：通用CAR-T细胞膜首次人体内实验放射治疗病情恶化/难治适度T细胞膜急适度淋巴细胞膜帕金森氏症（r/r T-ALL）的安全适度和。联席会议：开发中的放射治疗技术-免疫放射治疗。编者：王以恰巧等参考资料：3013名片：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在中后期食管柱状细胞膜乳癌病患中的应使用：一项随机的停止使用标记II期实验（ORIENT-2）。联席会议：小肠乳癌-胃部食管乳癌、胰腺乳癌和肾脏胆道乳癌编者：徐建明大学教授等参考资料：4511名片：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异适度CAR-T细胞膜对髓母细胞膜瘤的禁绝适度放射治疗联席会议：中枢神经系统编者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东参考资料：2522名片。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在中后期错配修复缺陷病患中的应使用联席会议：开发中的放射治疗学-免疫放射治疗编者：沈琳大学教授等参考资料：3021名片。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART放射治疗病情恶化/难治适度ACUTE淋巴细胞膜帕金森氏症/乳乳癌的首例人体内临床实验联席会议: 开发适度放射治疗学-免疫放射治疗编者简介：张明志，杨林等参考资料：3026名片: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）联合行动应使用于中后期虚拟瘤病患的Ib期研究者联席会议：发展适度放射治疗学--分子靶向药物和分子生物学编者：龚继芳，沈琳大学教授等参考资料：3523名片：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin联合行动紫杉醇和nedaplatin放射治疗暂时适度或分散适度食管柱状细胞膜乳癌（ESCC）病患的II期研究者。联席会议：小肠乳癌-胃部食管、胰腺和肾脏胆道乳癌的研究者编者：王以志强，李玉红，王以德申，王以凤华，任超，谭琼 王以志强、李玉红、王以德深、王以凤华、任超、谭琼参考资料：4522名片：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.联席会议：小肠乳癌-胃部食管乳癌、胰腺乳癌和肾脏胃乳癌的二线放射治疗编者：宋艳等参考资料：4524名片：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体环状RNA均值使用初始活检时检查高等级乳癌的尿液外体环状RNA均值：一项多中心的回顾适度研究者联席会议：泌尿生殖系统结核病---乳癌、睾丸乳癌和乳癌编者简介：Liaoyuan Li等参考资料：5522名片。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 大面积中后期宫颈乳癌并发化学疗法后的基本功能化学疗法联席会议: 妇科结核病编者简介： 李珉珉等参考资料：6031名片：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼放射治疗肾上腺髓适度乳癌的相关适度：基于ALTER01031实验的比对。会话：鳞状编者：长春市诊所娴熟大学教授参考资料：6526名片。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄组对安洛替尼放射治疗后病患情节的冲击: ALTER01031的亚组比对联席会议：鳞状编者：长春市诊所娴熟大学教授参考资料：6527名片。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA比对预测I-IIIA期非小细胞膜前列腺乳癌（NSCLC）病患术后病情恶化: GASTO1035和GASTO1018的结果联席会议：前列腺乳癌-非小细胞膜大面积-区域适度/小细胞膜/小细胞膜/其他胸科结核病编者：Si-Yu Wang等参考资料：9023名片：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞膜前列腺乳癌（NSCLC）中EGFR组氨酸嘌呤类似物的新型青霉素前提联席会议:前列腺乳癌-非小细胞膜分散适度前列腺乳癌编者简介：赵昕，金玲玲，满宇，欧真假，湛，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧真假、湛、薛武、杨绍、范敏参考资料：9528名片：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1实验中中后期卵巢乳癌总生存的替代终点联席会议：卵巢乳癌/皮肤乳癌编者：聂润聪，袁书强，李元芳，陈英波，周志伟 聂润聪、袁书强、李元芳、陈英波、周志伟参考资料：10030名片：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼放射治疗病情恶化或分散适度原发适度恶适度骨病患的II期研究者联席会议： 畸形编者：唐丽娜，牛晓辉，王以震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王以振、蔡启庆、涂崇奇、范正福、杨瑶参考资料：11525名片。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步口碑安罗替尼在中后期畸形病患多线放射治疗中的安全适度和。联席会议：畸形编者：姚伟涛，王以家强，张春，王以欣，杜新辉，田志浩，牛晓颖 姚伟涛、王以家强、张春、王以鑫、杜鑫辉、田志超、牛晓英参考资料：11526名片：414